Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

DiA Imaging Analysis Collaborates with Intel Corporation to Accelerate Processing Time of its AI-based Cardiac Ultrasound Software in Hospitals

DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software, has teamed up with Intelto streamline artificial intelligence (AI) solutions used by echocardiography (Echo) labs. DiA’s AI-based software, LVivo Seamless™, automatically analyzes cardiac ultrasound images using the Intel® Distribution of OpenVINO™ toolkit, to optimize processing time by over 40% percent while maintaining accuracy.

The ability to view key cardiac measurements results quickly after each scan is vital to the Echo Lab workflow.

DiA Imaging Analysis LVivo Seamless™ algorithm runs automatically on cardiac ultrasound exams, selecting and analyzing the optimal cardiac views to generate key measurements that help identify clinical indications – that are otherwise difficult to find visually or manually. DiA’s solutions enable sonographers and cardiologists to analyze higher scan volumes in a quicker and reproducible way, optimizing their everyday workflows.

“Intel is committed to creating world-changing technology that helps advance patient care. Our edge-to-cloud infrastructure technology supports rich data analysis environments like DiA Imaging Analysis was able to optimize the processing time of its AI-based models by over 40% percent when running on local hospital IT infrastructure based on Intel CPUs, without requiring the use of a discrete graphics processing unit (GPU) or integration of more complex IT  infrastructures. LVivo Seamless, where time and accuracy are crucial elements,” said Alex Flores, Head of  Global Health Solutions at Intel Corporation.

By working with Intel, DiA Imaging Analysis was able to optimize the processing time of its AI-based models by over 40% percent when running on local hospital IT infrastructure based on Intel CPUs, without requiring the use of a discrete graphics processing unit (GPU) or integration of more complex IT  infrastructures.

“Every minute counts in a busy echocardiography environment. Using an AI solution like LVivo  Seamless that automatically runs ‘behind the scenes’ on hospital servers eliminates many manual and visual steps involved with both cardiac ultrasound view selection and measurement,” said Hila Goldman Aslan, CEO, and co-founder of DiA Imaging Analysis. “We are thrilled to work closely with Intel, leveraging AI to make the analysis of ultrasound images smarter, faster, and  more accessible.”

DiA Imaging Analysis is a leading provider of FDA-cleared and CE marked ultrasound AI  software solutions that automate the way clinicians use and analyze ultrasound scans. The company’s LVivo product line for cardiac and abdominal auto analysis allows clinicians with varying levels of ultrasound experience to automatically analyze ultrasound images on their ultrasound devices and healthcare IT systems with increased speed, efficiency, and accuracy.  DiA serves thousands of end-users worldwide.  

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy